Interepidemic Rift Valley fever in East Africa: the recent risk landscape and projected impacts of global change
Proceedings of the Royal Society B: Biological Sciences · 2026
DOI: 10.1098/rspb.2025.2193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the Royal Society B: Biological Sciences, 2026. Verfasst von Evan A Eskew und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Interdisciplinary Data Sciences, University of Idaho, Moscow, ID, USA. Hauptthemen laut MEDLINE: Rift Valley Fever, Climate Change. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, National Institute of Allergy and Infectious Diseases, NIGMS NIH HHS.
Abstract (Originalsprache)
Rift Valley fever (RVF) is a zoonotic disease that causes sporadic, multi-country epidemics. However, there is limited understanding of RVF virus circulation during interepidemic periods and the potential impacts of global change on interepidemic RVF. To address these knowledge gaps, we built a predictive model using recent interepidemic RVF outbreak data from Kenya, Tanzania and Uganda. We then projected interepidemic RVF risk for three future time periods (2021–2040, 2041–2060, 2061–2080) under three global change scenarios representing different trajectories for climate and human population distribution (SSP126, SSP245, SSP370). Our model identified interepidemic RVF risk hotspots in east Kenya, east Tanzania and southwest Uganda. Hydrology was a major driver of disease risk: hotspots emerged in association with lakes and rivers, and risk peaked during May–July following the long rains season (March–May). Projections under global change scenarios suggested that disease risk will generally decrease over time. Nevertheless, owing to expected human population growth, we estimate that > 90 million people in the study region will be exposed to interepidemic RVF by 2061–2080, which is nearly double the historical (1970–2000) estimate of approximately 49 million people. Mitigating the future health impacts of RVF will require increased disease surveillance, prevention and control effort in risk hotspots.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Interdisciplinary Data Sciences, University of Idaho, Moscow, ID, USA.
- Paul G. Allen School for Global Health, Washington State University, Pullman, WA, USA.
- School of the Environment, Washington State University, Vancouver, WA, USA.
- Global Health-Kenya, Washington State University, Nairobi, Kenya.
- Department of Animal Science, Pwani University, Kilifi, Kenya.
- Department of Biosecurity, Ecosystems and Veterinary Public Health, Makerere University, Kampala, Uganda.
ORCID-Profile: Evan A Eskew, Erin Clancey, Scott L Nuismer
Förderung
- FIC NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIGMS NIH HHS
- Coalition for Epidemic Preparedness Innovations
- NIAID NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Eskew, E. A., Clancey, E., Singh, D., Situma, S., Nyakarahuka, L., Njenga, M. K., & Nuismer, S. L. (2026). Interepidemic Rift Valley fever in East Africa: the recent risk landscape and projected impacts of global change. Proceedings of the Royal Society B: Biological Sciences. https://doi.org/10.1098/rspb.2025.2193
Vancouver
Eskew EA, Clancey E, Singh D, Situma S, Nyakarahuka L, Njenga MK, et al. Interepidemic Rift Valley fever in East Africa: the recent risk landscape and projected impacts of global change. Proceedings of the Royal Society B: Biological Sciences. 2026. doi:10.1098/rspb.2025.2193
BibTeX
@article{Eskew2026,
author = {Eskew, Evan A and Clancey, Erin and Singh, Deepti and Situma, Silvia and Nyakarahuka, Luke and Njenga, M Kariuki and Nuismer, Scott L},
title = {Interepidemic Rift Valley fever in East Africa: the recent risk landscape and projected impacts of global change},
journal = {Proceedings of the Royal Society B: Biological Sciences},
year = {2026},
doi = {10.1098/rspb.2025.2193}
}
EUVIMED